pembrolizumab
PulseAugur coverage of pembrolizumab — every cluster mentioning pembrolizumab across labs, papers, and developer communities, ranked by signal.
3 day(s) with sentiment data
-
AI-developed cancer vaccine shows promise, but high cost raises accessibility concerns · 1 source tracked
Moderna and Merck's personalized mRNA cancer vaccine, Intismeran Autogene, has shown promising results in Phase III clinical trials for melanoma, marking a significant milestone as the first individualized neoantigen th…
-
AI helps design cancer treatment that clears Phase 3 trials
Moderna and Merck have reported positive Phase 3 results for an individualized mRNA cancer therapy that utilizes AI to identify neoantigens most likely to trigger an immune response. The AI algorithms analyze a patient'…
-
Merck, Moderna melanoma vaccine shows promise in Phase 3 trial
Merck and Moderna have announced promising results from a Phase 3 clinical trial for their personalized mRNA vaccine, intismeran autogene, when used in combination with Merck's Keytruda immunotherapy for melanoma patien…
-
Trump Admin Moves to Close Medicare Drug Price Negotiation Loophole
The Trump administration, through the Centers for Medicare and Medicaid Services (CMS), is proposing to close a loophole in the Inflation Reduction Act (IRA) that allowed drugmakers to avoid Medicare price negotiations.…
-
Healthcare M&A Surges to $65B Amid Patent Cliffs and Global Innovation
The pharmaceutical industry is experiencing a significant surge in mergers and acquisitions, with $65 billion in deals during the first quarter of 2026. This trend is driven by looming patent expirations for major drugs…
-
TIGIT cancer drugs fail to replicate Keytruda's success
The article discusses TIGIT drugs, a class of cancer immunotherapies that have largely failed to deliver on their initial promise. Similar to the disappointing amyloid-beta drugs for Alzheimer's, TIGIT drugs were develo…
-
AI accelerates cancer drug discovery, immunotherapy advances show promise
Artificial intelligence is accelerating drug discovery for cancer treatments by rapidly identifying potential compounds. AI algorithms are also being integrated into clinical trial designs to improve efficiency and redu…
-
Noetik licenses AI models to GSK for $50M to improve cancer trial success rates
Noetik, a biotech company, is leveraging AI, specifically transformer models like TARIO-2, to address the high failure rate in cancer clinical trials. Their approach focuses on better matching patients with specific tum…